Home About Chat Users Issues Party Candidates Polling Firms Media News Polls Calendar Key Races United States President Senate House Governors International

New User Account
"A comprehensive, collaborative elections resource." 
Email: Password:

  FDA's Retention Bonuses Rise to the Top
NEWS DETAILS
Parent(s) Container 
ContributorScottĀ³ 
Last EditedScottĀ³  Aug 02, 2007 06:05am
Logged 0
CategoryNews
MediaNewspaper - Washington Post
News DateThursday, August 2, 2007 12:00:00 PM UTC0:0
DescriptionWashington Post article.

An excerpt...
"Before paying $48,823 in cash bonuses to its chief of regulatory affairs in 2005, the Food and Drug Administration asked her to sign a simple declaration: "If I am unable to receive a retention allowance, I am likely to leave the federal government for a higher paying position in the private sector," wrote Margaret O'K. Glavin.

Glavin's statement did not detail a specific job offer, but that did not impede the payment. Over the past 4 1/2 years, she has collected more than $178,000 in cash bonuses -- on top of her $159,840 annual salary.

FDA officials justified Glavin's bonuses by saying her pay should be close to the salaries of those employed by companies she regulates, namely Washington lobbyists. The private-sector comparison has prompted large cash bonuses for top agency officials to quadruple since 2002, to $13.6 million in 2005, according to FDA officials and salary information provided to Congress.

The bonuses were paid during a rough patch at the FDA, encompassing a shortage of flu vaccine and embarrassing recalls of the pain-relieving drug Vioxx and malfunctioning heart defibrillators. Throughout, the agency repeatedly insisted that it lacked the resources to conduct adequate food and drug inspections.

The payments, which have attracted bipartisan criticism from lawmakers, offer an unusually detailed look at how the administration has implemented a cash bonus program that Congress expanded in 2004 to attract and retain talented federal employees.

Lawmakers say that at the FDA, many of the bonuses went to the highest-paid officials rather than the scientists, inspectors and doctors most at risk of jumping to the private sector. To critics, the payments bore little relationship to the agency's performance and reputation or to the likelihood that someone might depart. Agency officials disagree and call the program a success."
Share
ArticleRead Full Article

NEWS
Date Category Headline Article Contributor

DISCUSSION